---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-26-000006"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:48:36.524778+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B

## Summary
- Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.
- GAAP diluted EPS $0.54 vs $0.95; non-GAAP diluted EPS $0.76 vs $1.13.
- FY2026 revenue guidance raised to $3.825B-$3.925B, implying ~20% YoY growth at midpoint.
- Operating cash flow $221M; closed $3.7B non-convertible debt to fund Amicus acquisition.
- Enzyme Therapies revenue up 6% to $514M; VOXZOGO $220M (+3%); $31M charge for NAGLAZYME campaign.

## SEC filing metadata
- accession: 0001048477-26-000006
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/0001048477-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/bmrn-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-26-000006
- JSON: https://secwatch.observer/filing/0001048477-26-000006.json
- Plain text: https://secwatch.observer/filing/0001048477-26-000006.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC reported the first quarter ended March 31, 2026 results: revenue $766 million, net income $106 million. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $766 million
  - Net income: $106 million
  - Guidance: raised
  - Result: reported results
  source text: Total Revenues for the first quarter of 2026 were $766 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/0001048477-26-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.